Evidence map›Paper›PMID 19681889›Full record

ArticleBritish journal of pharmacology2009

Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression.

Hua-Qin Wang, Bao-Qin Liu, Yan-Yan Gao, Xin Meng, Yifu Guan, Hai-Yan Zhang, Zhen-Xian Du

Abstract read
In one paragraph

Article in British journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. MLN2238 exerts its anti-tumor effectsFrontiers in pharmacology · 2022
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. BAG3 protects against hyperthermic stress by modulating NF-κB and ERK activities in human retinoblastoma cells.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2015
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hua-Qin WangDepartment of Biochemistry & Molecular Biology, China Medical University, Shenyang, China. wanghq_doctor@hotmail.com
Bao-Qin Liu
Yan-Yan Gao
Xin Meng
Yifu Guan
Hai-Yan Zhang
Zhen-Xian Du

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeProteasome inhibitors represent a novel class of anti-tumour agents that have clinical efficacy against haematological and solid cancers. The anti-apoptotic protein BAG3 is a member of the Bcl-2-associated athanogene family. We have previously shown that BAG3 is up-regulated after exposure to proteasome inhibitors and that inhibition of BAG3 sensitized cells to apoptosis induced by proteasome inhibition. However, the mechanisms by which proteasome inhibition induced BAG3 expression remained unclear and the present experiments were designed to elucidate these mechanisms. EXPERIMENTAL APPROACH: Effects of the proteasome inhibitor MG132 on activation of mitogenic signalling pathways were evaluated in kidney cancer cells (A498, Caki1, Caki2), with Western blotting. Specific inhibitors against individual mitogenic signalling pathways, real-time reverse transcription-polymerase chain reaction and luciferase reporter assays were used to investigate the roles of mitogenic signalling pathways in BAG3 induction after proteasome inhibition. Cell death was evaluated using Annexin V/propidium iodide staining and subsequent FACS. KEY

resultsMG132 activated several key mitogenic signalling pathways including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) activities. Induction of BAG3 by MG132 was inhibited by blocking JNK, but not ERK1/2 and p38 MAPK signalling pathways. In addition, SP600125 and dominant-negative JNK1 suppressed BAG3 promoter-driven reporter gene expression. Furthermore, activation of the JNK pathway induced BAG in kidney cancer cells after treatment with MG132. CONCLUSIONS AND IMPLICATIONS: Our results suggested that the JNK pathway was associated with the protective response against proteasome inhibition, by mediating induction of BAG3.

Indexed as

ApoptosisProteasome InhibitorsAdaptor Proteins, Signal TransducingAnthracenesApoptosis Regulatory ProteinsCell Line, TumorExtracellular Signal-Regulated MAP KinasesFlavonoidsHumansImidazolesJNK Mitogen-Activated Protein KinasesKidney NeoplasmsLeupeptinsMitogen-Activated Protein Kinase 8p38 Mitogen-Activated Protein KinasesPyridines2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-oneAdaptor Proteins, Signal TransducingAnthracenesApoptosis Regulatory ProteinsBAG3 protein, humanbenzyloxycarbonylleucyl-leucyl-leucine aldehydeExtracellular Signal-Regulated MAP KinasesFlavonoidsImidazolesJNK Mitogen-Activated Protein KinasesLeupeptinsMitogen-Activated Protein Kinase 8p38 Mitogen-Activated Protein KinasesProteasome InhibitorspyrazolanthronePyridinesSB 203580

Identifiers

PMID19681889
PMCPMC2782350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.